Contact
Please use this form to send email to PR contact of this press release:
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
TO: